TG Therapeutics gains amid takeover speculation

TG Therapeutics gains amid takeover speculation
TG Therapeutics signs manufacturing supply agreement with FUJIFILM Diosynth Biotechnologies
STARTS NOW! Rebel's Edge 🏴☠️ 1pm Line up Jackson Hole Symposium insights into future monetary policy. $AMD $ZIM $TGTX $XPEV Sports 🏈 @petenajarian NCAAFootball is back Saturday from Dublin, Fla St v Georgia Tech NFL: QB- Young guns 6 of the 1st 12 picks who stands out? https://t.co/m3sQfshJZb
Last week was the busiest for S&P 500 companies reporting #earnings, but this is the week that counts with 1,200 companies set to report and $IWM in focus. https://t.co/oMi4gKp1GN ... oh, and $AAPL $SPY $STNG $SMCI $ALX $TGTX $SBT $ACMR $FUBO $WING $MSTR $CHGG $CEIX $SJW… https://t.co/VnxHiKbVM4
9.37BUSD
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US88322Q1085
CUSIP
048785109
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
21.80
PEG Ratio
1.61
Book Value
4.26
Dividend Share
-
Dividend Yield
-
Earnings Share
2.75
Wall Street Target Price
69.71
EPS Estimate Current Year
0.95
EPS Estimate Next Year
2.71
EPS Estimate Current Quarter
0.4386
EPS Estimate Next Quarter
0.4346
Most Recent Quarter
-
Revenue TTM
799,536,000
Gross Profit TTM
658,596,992
EBITDA
136,451,008
Profit Margin
55.22%
Return On Assets TTM
7.28%
Return On Equity TTM
100.28%
Revenue Per Share TTM
5.61
Qtly Revenue Growth YOY
70.30%
Diluted Eps TTM
2.75
Qtly Earnings Growth YOY
-70.60%
Trailing PE
21.80
Forward PE
28
Price Sales TTM
11.4784
Price Book MRQ
15.5024
Enterprise Value Revenue
11
Enterprise Value EBITDA
68
903.08
3.20%227.40
2.97%965.00
0.55%314.92
0.35%900.30
0.00%139.16
0.00%528.21
-4.77%355.10
-2.26%34.64
-2.01%153.70
-1.47%